Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Genitourinary 1Dermatologic 1

Conditions

Carcinoma, Basal Cell 11Skin Neoplasms 4Basal Cell Nevus Syndrome 4Neoplasms, Basal Cell 2Medulloblastoma 2Squamous Cell Carcinoma of Head and Neck 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Hematologic Neoplasms 1Eyelid Neoplasms 1Endometrial Neoplasms 1Colonic Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1

Interventions

pembrolizumab 27Nivolumab 20atezolizumab 6Ipilimumab 6Magnetic Resonance Spectroscopy 5Specimen Handling 4Paclitaxel 4Docetaxel 4Cyclophosphamide 4Carboplatin 4fludarabine 3avelumab 3Pemetrexed 3Interleukin-2 3tislelizumab 2epacadostat 2durvalumab 2aldesleukin 2Taxes 2Radiosurgery 2Cisplatin 2veliparib 1toripalimab 1spartalizumab 1sotigalimab 1sonidegib 1sargramostim 1regorafenib 1poly ICLC 1liposomal doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Transitional Cell × sonidegib × Dermatologic × Clear all
NCT04007744 2026-03-18

Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors

Mayo Clinic

Phase 1 Active not recruiting
36 enrolled
DermatologicGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Lung Neoplasms, Melanoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡